GEN 003

Drug Profile

GEN 003

Alternative Names: GEN-003; Herpes simplex virus type 2 therapeutic vaccine - Genocea Biosciences; HSV-2 Tx - Genocea Biosciences; HSV-2 vaccine - Genocea Biosciences

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Genocea Biosciences
  • Class Antivirals; Subunit vaccines; Viral vaccines
  • Mechanism of Action B cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Herpes simplex virus type 2 infections

Most Recent Events

  • 16 Feb 2017 Genocea Biosciences plans phase III trials for Herpes simplex virus type-2 alone and in combination with oral anti-viral therapy in the fourth quarter of 2017
  • 05 Jan 2017 Efficacy data from a phase IIb trial in Herpes simplex virus type-2 infections released by Genocea Biosciences
  • 28 Oct 2016 Immunogenicity data from a phase IIa trial in Herpes simplex virus type-2 infections released by Genocea Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top